Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Krystal Biotech Inc is a biotechnology business based in the US. Krystal Biotech shares (KRYS) are listed on the NASDAQ and all prices are listed in US Dollars. Krystal Biotech employs 75 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $57.06 |
|---|---|
| 52-week range | $38.86 - $102.99 |
| 50-day moving average | $63.30 |
| 200-day moving average | $62.06 |
| Wall St. target price | $126.86 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.72 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $57.06 from 2022-01-24
| 1 week (2022-01-18) | -3.94% |
|---|---|
| 1 month (2021-12-22) | N/A |
| 3 months (2021-10-26) | 4.81% |
| 6 months (2021-07-26) | -0.56% |
| 1 year (2021-01-26) | -19.83% |
|---|---|
| 2 years (2020-01-24) | 1.86% |
| 3 years (2019-01-25) | 146.27% |
| 5 years (2017-01-22) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -9.31% |
| Return on equity TTM | -16.38% |
| Profit margin | 0% |
| Book value | $18.36 |
| Market capitalisation | $1.4 billion |
TTM: trailing 12 months
We're not expecting Krystal Biotech to pay a dividend over the next 12 months.
Over the last 12 months, Krystal Biotech's shares have ranged in value from as little as $38.856 up to $102.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Krystal Biotech's is 0.9062. This would suggest that Krystal Biotech's shares are less volatile than average (for this exchange).
Krystal Biotech, Inc. , a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx for other rare lung disease. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.